CTI investigated by SEC
This article was originally published in The Gray Sheet
Executive Summary
The Securities & Exchange Commission and U.S. Attorney request documents from Computerized Thermal Imaging's management related to possible insider trading malfeasance, company states in recent 10-K filing. While CTI maintains the allegations are without merit, it believes the charges will greatly impair its ability to raise funds. FDA's Radiological Devices Advisory panel voted against approval of the company's BCS 2100 breast imaging system; CTI continues to work with the agency to remedy deficiencies in its application (1"The Gray Sheet" May 25, 2003, In Brief)...